Kuros Biosciences【0RHR】銘柄情報

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

8.56

( - )

買値

8.56

売値

8.56

出来高

74,659

0.00 日の範囲 0.00

8.56 52 週間の範囲 8.56

時価総額

337.601M

前日終値

8.56

始値

時刻

416

18.455

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

CHF 196,600

発行済株式数

39,439,421

配当利回り

PER

424.24

1 株当たり利益 (EPS)

0.06

歳入

146.06M

純利益

2.55M

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Gran... Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

kurosbio.com

本社

Schlieren, Switzerland

設立

2026

Kuros Biosciences AG is listed in the sector of the ロンドン証券取引所 with ticker 0RHR. The last closing price for Kuros Biosciences was CHF8.56. Over the last year, Kuros Biosciences shares have traded in a share price range of CHF 8.56 to CHF 8.56.

Kuros Biosciences currently has 39,439,421 shares in issue. The market capitalisation of Kuros Biosciences is CHF337.60 million. Kuros Biosciences has a price to earnings ratio (PE ratio) of 424.24.

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Kuros...

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Annual General Meeting of Kuros Biosciences approves all resolutions...

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Ad hoc announcement pursuant to Article 53 of the...

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Ad-hoc announcement pursuant to Article 53 of the...

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences Kuros Biosciences to provide investor updateat Octavian and...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual...

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 Ad hoc...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Kuros Biosciences debuts commercial launch of MagnetOs...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	8.56	8.56	8.56	16173	8.56	DE
52	8.56	8.56	8.56	15645	8.56	DE
156	8.56	8.56	8.56	10146	8.56	DE
260	8.56	8.56	8.56	5946	8.56	DE

0RHR - Frequently Asked Questions (FAQ)

What is the current Kuros Biosciences AG share price?

The current share price of Kuros Biosciences AG is CHF 8.56

How many Kuros Biosciences AG shares are in issue?

Kuros Biosciences AG has 39,439,421 shares in issue

What is the market cap of Kuros Biosciences AG?

The market capitalisation of Kuros Biosciences AG is CHF 337.6M

What is the 1 year trading range for Kuros Biosciences AG share price?

Kuros Biosciences AG has traded in the range of CHF 8.56 to CHF 8.56 during the past year

What is the PE ratio of Kuros Biosciences AG?

The price to earnings ratio of Kuros Biosciences AG is 424.24

What is the cash to sales ratio of Kuros Biosciences AG?

The cash to sales ratio of Kuros Biosciences AG is 6.87

What is the registered address of Kuros Biosciences AG?

The registered address for Kuros Biosciences AG is Wagistrasse 25, Schlieren, Zurich, 8952

What is the Kuros Biosciences AG website address?

The website address for Kuros Biosciences AG is kurosbio.com

skitahoe 4分前

I understand a brokerage may not charge for buying or selling stock. That said, who would buy or sell 100 shares of a company selling for $.001X for any purpose other than manipulation of the stock price. What brokerage is permitting such trades?

The company clearly needs to file th

CRTG

Dennis14 6分前

I can’t stand those R.S’s all they’re doing is robbing the share holder. Plan and simple.

WNBDD

Mr. Bill 8分前

Martin Armstrong on AI and AI replacing computer programmers etc

https://www.brighteon.com/7ceef81e-b762-4487-9785-c00b8d22d260

Latenightmike57 8分前

Too bad there's no gold at Skull Valley.
Even if they could mine there, which they can’t, there’s nothing there to take out of that dirt except more dirt.

Rite is just the regurgitated form of NMCX and the crook Michael Sheppard

RITE

Tr8dervic 17分前

Lol, not there yet, knock on wood!

theorysuit 17分前

No use to argue with any of this pump crew and their numerous aliases. Just keep putting out the truth. I'm still not convinced any of them actually have any shares

NWBO

zooey 19分前

Here’s another question:
Why did you repeatedly ask Tony to pay you to promote APRU?

APRU

silvr_surfr 20分前

Ok, so it's a bone, but the HHS just implemented label changes for men's testosterone to "follow the science". Here's what was said in the article:

“As our understanding of testosterone therapy continues to evolve, prescribing information should reflect the best available science,” sa

ANIP

MasterBlastr 20分前

Was sweating out the cut line, with Matsu and Gotterup in on the number. But, I got a family, and family is everything.

https://i.postimg.cc/GmGsqkBt/DK-260619-1.jpg

jara-mill 22分前

HUUUUGE ANNOUNCEMENTS of HUUUUGE ACCOMPLISHMENTS IMMINENT!!! REALLY REALLY HUUUUGE WHALES LURKING AND VERY HANGRY!!! ONWARD!!!

This is OUR Odyssey!

HHSE

MasterBlastr 22分前

Where's my Glipizide . . .

firebag1 23分前

Sure

TWOH

firebag1 24分前

You’ve always been snarky. Takes one to know one.

TWOH

ErnieBilco 25分前

They must be pretty sure because it isn't even being voted on at their annual meeting on Monday.

UNLESS THEY SNEAK IT IN UNDER "OTHER BUSINESS"

UNCY

jara-mill 30分前

$HHSE: The harder we work... the luckier we get...

Sunday May 31st, 2026

(Click on this link to view photos)

https://hannoverhousemovies.blogspot.com/2026/05/the-harder-we-work-luckier-we-get.html HHSE Blog - Latest News

Dear HHSE Friend

HHSE

rosemountbomber 31分前

Another 8 days above $1 and they won’t have to do a RS

UNCY

iamadog 31分前

People need to research a posters history . Not that what was posted will make a difference it just the fact of why even answer when there is no enrichment .

layton 32分前

They must be bots.....

PSRU

Tr8dervic 33分前

Reese's snack size peanut butter cups, pop the whole thing in at once, lol

tat4tat 33分前

Why exactly is an NDA necessary when it seems to already be public knowledge except for the monetary amount. What is so sensirive about whether or not the amount is 8,000 or 8,000,000?

BIEI

danieldeubank 34分前

Cold Dark Hole,
Yeah, timelines have slipped and the "niobium alone pays the bills" vibe from older studies didn't fully survive contact with reality — capex inflated, markets shifted, and here we are a decade later still de-risking. Hindsight's 20/20, and plenty of projects (not just NB) ha

shajandr 38分前

The rule of thumb in pennystocks is that the post-RS price will decay 80 percent in the first 6 months.

https://investorshub.advfn.com/uimage/uploads/2026/6/19/ddnpflaffer2.jpg

"Suffer" schadenfreude?? LOLOL! No suffering in laffing at pennychumps loosing munny in penn

TLSS

MasterBlastr 38分前

Mine too, with Reese's and Payday a close second. I put mine in the fridge so I can more easily nibble off the chocolate coating first.

Investor082 38分前

Did you ever think Flipper’s new BS theories for the last 13 years were funny? LOL! ;)

How many retail families get impacted because he and other minions continue to set false expectations?

NWBO

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Kuros Biosciences AG (0RHR)

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Kuros Biosciences AG について

0RHR 最新ニュース

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros statement on media inquiry concerning former Board member

Kuros Biosciences announces changes in the Board of Directors

0RHR - Frequently Asked Questions (FAQ)

0RHR 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する